The teams at Decode Health and IQuity Labs have collaborated for several years leveraging AI to deliver on the power of genomic data. Today, the companies announced they will now operate as Decode Health.
IQuity’s NIH-funded research in autoimmune disease detection and monitoring will support Decode Health’s mission to solve complex healthcare problems using data. This combination of expertise will further enhance Decode Health’s ability to create data assets, products and services to improve patient outcomes, lower costs and promote health equity. A healthcare AI company, Decode Health partners with industry-leading diagnostic companies, pharma and care management providers to unlock discoveries within their data.
Over the last several years, IQuity’s research in RNA and genomics, combined with Decode’s healthcare AI/machine learning expertise, has produced new tools to predict outcomes and monitor disease risk in autoimmune conditions, including Multiple Sclerosis and inflammatory bowel disease. Over time, IQuity has extended its research into other disease areas including neurodegenerative diseases. These approaches help care teams detect disease risk at the molecular level to improve outcomes. Since inception, IQuity has received more than $3.5M in federal research grants from the National Institute of Allergy and Infectious Disease (NIAID) and National Institute on Aging (NIA) at National Institutes of Health (NIH).
Both Decode Health and IQuity were co-founded by Chase Spurlock, PhD, and Julia Polk. Since Decode’s founding, Spurlock has served as its Chief Executive Officer, while Polk has served as Chief Strategy Officer and currently serves as an Executive Advisor to the company.